Condition: Metastatic Renal Cell Carcinoma · Sponsor: National Taiwan University Hospital
The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.
This description comes directly from the study's public registry record.
Yeong Shiau Pu, MD PhD · 886-2-23123456 · pu5249@ntuh.gov.tw
Chung Hsin Chen, MD PhD · 886-2-23123456 · mufasachen@gmail.com
Always discuss trial participation with your own doctor first.
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04712305